Advertisement

Axillary nodal metastases from carcinoma of unknown primary (CUPAx): a systematic review of published evidence

  • George Pentheroudakis
  • George Lazaridis
  • Nicholas Pavlidis
Review

Abstract

Axillary lymph node metastases from adenocarcinoma or poorly differentiated carcinoma of unknown primary (CUPAx) represent a rare clinical entity without consensus on its biology, management and outcome. We systematically reviewed published CUPAx series and identified 24 retrospective studies enrolling 689 patients from 1975 till 2006. CUPAx affected women at a mean age of 52 years, 66% of whom post-menopausal harbouring low-volume (N1, 48%) or high-volume (52%) nodal disease from ductal adenocarcinoma (83%). Among a total of 446 patients managed with mastectomy, a small breast primary was identified histologically in 321 (72% of cases). Hormone receptor protein expression was observed in 40–50% of cases, while HER2 overexpression in 31%. CUPAx patients were managed with axillary lymph node dissection coupled to mastectomy (59%), primary breast irradiation (26%) or observation (15%). Observation was associated with high locoregional relapse rates (42%) and risk of metastatic spread. Mastectomy or radiotherapy provided locoregional disease control in 75–85% of cases, while adjuvant systemic therapy was associated with a non-significant trend for improved survival in few series. Five-year survival ranged from 59.4 to 88% at a median follow-up of 62 months (mean 5-year survival 72%), with axillary tumour burden being the pivotal prognostic factor. CUPAx is associated with similar presentation, biology and outcome to resected node-positive overt breast cancer and should be treated accordingly.

Keywords

Axillary metastases Cancer of unknown primary Prognosis 

Notes

Conflict of interest statement

The authors declare that they have no actual or potential conflict of interest including any financial, personal or other relationships with other people or organizations within that could inappropriately influence (bias) their work.

Supplementary material

10549_2009_554_MOESM1_ESM.pdf (34 kb)
(PDF 34 kb)

References

  1. 1.
    Pavlidis N, Briasoulis E, Hainsworth J, Greco FA (2003) Diagnostic and therapeutic management of cancer of unknown primary. Eur J Cancer 39:1990–2005CrossRefPubMedGoogle Scholar
  2. 2.
    Pierce EH, Gray HK, Dockerty MB (1973) Surgical significance of isolated axillary adenopathy. Surgery 145:104–107Google Scholar
  3. 3.
    Copeland EM, McBride CM (1973) Axillary metastases from unknown primary sites. Ann Surg 178:25–28PubMedGoogle Scholar
  4. 4.
    Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009) Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6):e1000097. doi: 10.1371/journal.pmed1000097 CrossRefPubMedGoogle Scholar
  5. 5.
    Owen HW, Dockerty MB, Gray HK (1954) Occult carcinoma of breast. Surg Gynecol Obstet 98:302–304PubMedGoogle Scholar
  6. 6.
    Feuerman L, Attie JN, Rosenberg B (1962) Carcinoma in axillary lymph nodes as an indicator of breast cancer. Surg Gynecol Obstet 114:5–8PubMedGoogle Scholar
  7. 7.
    Fitts WT, Steiner GC, Enterline HT (1963) Prognosis in occult carcinoma of the breast. Am J Surg 106:460–463CrossRefGoogle Scholar
  8. 8.
    Haagensen CD (1971) The diagnosis of breast carcinoma. In: Haagensen CD (ed) Diseases of the breast. WB Saunders, Philadelphia, pp 478–502Google Scholar
  9. 9.
    Ashikari R, Rosen PP, Urban JA, Senoo T (1976) Breast cancer presenting as an axillary mass. Ann Surg 183:415–417CrossRefPubMedGoogle Scholar
  10. 10.
    Feigenberg Z, Zer M, Dintsman M (1976) Axillary metastases from an unknown primary source. Israel. J Med Sci 12:1153–1158Google Scholar
  11. 11.
    Vezzoni P, Balestrazzi A, Bignami P, Concolino F, Gennari L, Veronesi U (1979) Axillary lymph node metastases from occult carcinoma of the breast. Tumori 65:87–91PubMedGoogle Scholar
  12. 12.
    Kemeny MM, Rivera DE, Terz JJ, Benfield JR (1986) Occult primary adenocarcinoma with axillary metastases. Am J Surg 152:43–47CrossRefPubMedGoogle Scholar
  13. 13.
    Bhatia SK, Saclarides TJ, Witt TR, Bonomi PD, Anderson KM, Economou SG (1987) Hormone receptor studies in axillary metastases from occult breast cancers. Cancer 59:1170–1172CrossRefPubMedGoogle Scholar
  14. 14.
    Campana F, Fourquet A, Ashby MA, Sastre X, Jullien D, Schlienger P et al (1989) Presentation of axillary lymphadenopathy without detectable breast primary: experience at Institut Curie. Radiother Oncol 15:321–325CrossRefPubMedGoogle Scholar
  15. 15.
    Whillis D, Brown PW, Rodger A (1990) Adenocarcinoma from an unknown primary presenting in women with an axillary mass. Clin Oncol 2:92–198CrossRefGoogle Scholar
  16. 16.
    Rosen PP, Kimmel M (1990) Occult breast carcinoma presenting with axillary lymph node metastases. A follow-up study of 48 patients. Hum Pathol 21:518–524CrossRefPubMedGoogle Scholar
  17. 17.
    Ellerbroek N, Holmes F, Singletary E, Evans H, Oswald M, McNeese M (1990) Treatment of patients with isolated axillary nodal metastases from an occult primary carcinoma consistent with breast origin. Cancer 66:1461–1467CrossRefPubMedGoogle Scholar
  18. 18.
    Merson M, Andreola S, Galimberi V, Bufalino R, Marchini S, Veronesi U (1992) Breast carcinoma presenting as axillary metastases without evidence of a primary tumour. Cancer 70:504–508CrossRefPubMedGoogle Scholar
  19. 19.
    Svastics E, Ronay P, Bodo M (1993) Occult breast cancer presenting with axillary metastasis. Eur J Surg Oncol 19(Suppl 1):575–580PubMedGoogle Scholar
  20. 20.
    Van Ooijen B, Bontenbal M, Henzen-Logmans SC, Koper PCM (1993) Axillary nodal metastases from an occult primary consistent with breast carcinoma. Br J Surg 80(10):1299–1300CrossRefPubMedGoogle Scholar
  21. 21.
    Kyokane T, Akashi-Tanaka S, Matsui T, Fukutomi T (1995) Clinicopathological characteristics of non-palpable breast cancer presenting as an axillary mass. Breast Cancer 2:105–112CrossRefPubMedGoogle Scholar
  22. 22.
    Jackson B, Scot-Conner C, Moulder J (1995) Axillary metastasis from occult breast carcinoma: diagnosis and management. Am Surg 61:431–434PubMedGoogle Scholar
  23. 23.
    Foroudi F, Tiver KW (2000) Occult breast carcinoma presenting as axillary metastases. Int J Radiat Oncol Biol Phys 47:143–147PubMedGoogle Scholar
  24. 24.
    Vlastos G, Jean ME, Mirza AN, Mirza NQ, Kuerer HM, Ames FC et al (2001) Feasibility of breast preservation in the treatment of occult primary carcinoma presenting with axillary metastases. Ann Surg Oncol 8:425–431CrossRefPubMedGoogle Scholar
  25. 25.
    Medina-Franco H, Urist MM (2002) Occult breast carcinoma presenting with axillary lymph node metastases. Rev Invest Clin 54:204–208PubMedGoogle Scholar
  26. 26.
    Shannon C, Walsh G, Sapunar F, Ahern R, Smith I (2002) Occult primary breast carcinoma presenting as axillary lymphadenopathy. Breast 11:414–418CrossRefPubMedGoogle Scholar
  27. 27.
    Matsuoka K, Ohsumi S, Takashima S, Saeki T, Aogi K, Mandai K (2003) Occult breast carcinoma presenting with axillary lymph node metastases: Follow-up of eleven patients. Breast Cancer 10:330–334CrossRefPubMedGoogle Scholar
  28. 28.
    Blanchard DK, Farley DR (2004) Retrospective study of women presenting with axillary metastases from occult breast carcinoma. World J Surg 28:535–539CrossRefPubMedGoogle Scholar
  29. 29.
    Chen C, Orel SG, Harris E, Schnall MD, Czerniecki BJ, Solin LJ (2004) Outcome after treatment of patients with mammographically occult, MRI-detected breast cancer presenting with axillary lymphadenopathy. Clin Breast Cancer 5:72–77CrossRefPubMedGoogle Scholar
  30. 30.
    Varadarajan R, Edge SB, Yu J, Watroba N, Janarthanan BR (2006) Prognosis of occult breast carcinoma presenting as isolated axillary nodal metastasis. Oncology 71:456–459CrossRefPubMedGoogle Scholar
  31. 31.
    Iglehart JD, Ferguson BJ, Shingleton WW, Sabiston DC, Silva JS et al (1982) An ultrastructural analysis of breast carcinoma presenting as isolated axillary adenopathy. Ann Surg 196:8–13CrossRefPubMedGoogle Scholar
  32. 32.
    Vilcoq JE, Calle R, Ferne F, Veith F (1982) Conservative treatment of axillary adenopathy due to probable subclinical breast cancer. Arch Surg 117:1136–1138PubMedGoogle Scholar
  33. 33.
    Pentheroudakis G, Briasoulis GE, Pavlidis N (2007) Cancer of unknown primary site: missing primary or missing biology? Oncologist 12:418–425CrossRefPubMedGoogle Scholar
  34. 34.
    Haupt HM, Rosen PP, Kinne DW (1985) Breast carcinoma presenting with axillary lymph node metastases. Am J Surg Pathol 9:165–175CrossRefPubMedGoogle Scholar
  35. 35.
    Ko EY, Han BK, Shin JH, Kang SS (2007) Breast MRI for evaluating patients with metastatic axillary lymph node and initially negative mammography and sonography. Korean J Radiol 8:382–389CrossRefPubMedGoogle Scholar
  36. 36.
    DeMartinini W, Lehman C, Partridge S (2008) Breast MRI for cancer detection and characterization: a review of evidence-based clinical applications. Acad Radiol 15:408–416CrossRefGoogle Scholar
  37. 37.
    Olson JA, Morris EA, Van Zee KJ, Linehan DC, Borgen PI (2000) MR Imaging facilitates breast conservation for occult breast cancer. Ann Surg Oncol 7:411–415CrossRefPubMedGoogle Scholar
  38. 38.
    Bader AA, Tio J, Petru E, Buchner M, Pfahlberg A, Volkholz H et al (2002) T1 breast cancer: identification of patients at low risk of axillary lymph node metastases. Breast Cancer Res Treat 76(1):11–17CrossRefPubMedGoogle Scholar
  39. 39.
    Yip CH, Taib NA, Tan GH, Ng KL, Yoong BK, Choo WY (2009) Predictors of axillary lymph node metastases in breast cancer: is there a role for minimal axillary surgery? Worl J Surg 33(1):54–57CrossRefGoogle Scholar
  40. 40.
    Buzdar AU (2009) Role of biologic therapy and chemotherapy in hormone-receptor and HER2-positive breast cancer. Ann Oncol 20:993–999CrossRefPubMedGoogle Scholar
  41. 41.
    Bennett-Britton TM, Purushotham AD (2009) Understanding breast cancer related lymphedema. Surgeon 7:120–124CrossRefPubMedGoogle Scholar
  42. 42.
    Lacroix M, Toillon TR, Leclercq G (2004) Stable portrait of breast tumours during progression: data from biology, pathology and genetics. Endocr Relat Cancer 11:497–522CrossRefPubMedGoogle Scholar
  43. 43.
    Besana-Ciani I, Greenhall MJ (2008) The importance of margin status after breast conservative surgery and radiotherapy in node-positive patients: a follow-up of 10–15 years. Int Semin Surg Oncol 22:5–13Google Scholar
  44. 44.
    Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ (2009) Thresholds for therapies: highlights of the Saint Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. doi: 10.1093/annonc/mdp322
  45. 45.
    Newman LA, Singletary SE (2007) Overview of adjuvant systemic therapy in early stage breast cancer. Surg Clin North Am 87:499–509CrossRefPubMedGoogle Scholar
  46. 46.
    Pusztai L (2008) Current status of prognostic profiling in breast cancer. Oncologist 13:350–360CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2009

Authors and Affiliations

  • George Pentheroudakis
    • 1
  • George Lazaridis
    • 1
  • Nicholas Pavlidis
    • 1
  1. 1.Department of Medical OncologyIoannina University HospitalIoanninaGreece

Personalised recommendations